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Objectives. We sought to study the possible presence of Chla-
mydia pneumoniae in aortic valve stenosis (AVS).
Background. Inflammation and immune mechanisms are con-
sidered important for the pathogenesis of nonrheumatic AVS. All
chlamydial species are able to cause heart infections, and sero-
epidemiologic studies have indicated an association between
chronic C. pneumoniae infection and coronary artery disease.
Furthermore, the organism has been demonstrated in atheroscle-
rotic lesions.
Methods. Aortic valve specimens with varying degrees of mac-
roscopic disease were obtained from 35 subjects—17 consecutive
patients undergoing aortic valve replacement for treatment of
nonrheumatic AVS and 18 age-matched subjects at autopsy. The
possible presence of C. pneumoniae in aortic valves was studied by
immunohistochemical analysis, polymerase chain reaction or
transmission electron microscopy, or a combination of these.
Results. Positive immunohistochemical staining with C. pneu-
moniae specific antibody was found in 9 (53%) of 17 patients with
advanced aortic valve disease requiring surgical treatment (group
A), 8 (80%) of 10 cadavers with clearly macroscopic aortic valve
pathology (group B) and 1 (12%) of 8 grossly normal cadaver
control subjects (group C). Statistical significance with regard to
the presence of C. pneumoniae was found when combined diseased
subjects (groups A and B: total 17 of 27 subjects) were compared
with group C (p 5 0.018). However, when group A was compared
with group C, there was only marginal statistical significance (p 5
0.088). Finally, there was a strong statistical significance (p 5
0.015) when groups B and C were compared. Chlamydia pneu-
moniae DNA was also found in three stenotic valves, and in two of
the three tested valve specimens chlamydia-like particles were
seen by electron microscopy.
Conclusions. Chlamydia pneumoniae is frequently present in
nonrheumatic AVS. Similarly, the high number of C. pneumoniae
infections detected in the early lesions of “degenerative” AVS
suggest that this pathogen may play an etiologic role in the
development of this disease. The validity of this relation requires
additional study.
(J Am Coll Cardiol 1997;29:1054–9)
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Nonrheumatic aortic valve stenosis (AVS) has been regarded
as a degenerative process, but many features of an active
inflammatory process have recently been demonstrated in
developing lesions (1). The presence of activated T lympho-
cytes in stenotic valves supports immunologic mechanisms
possibly induced by a local antigen stimulus (2).
Chlamydia pneumoniae is a common human respiratory
pathogen (3–5) that has been linked to coronary artery disease
(CAD) and myocardial infarction in seroepidemiologic studies
(5–8) and has been demonstrated in specimens from athero-
sclerotic lesions (5,9–11). All chlamydial species have been
documented to cause heart infections, and Ward and Ward
(12) demonstrated in 1974 the presence of chlamydial antigen
in atrial and valve biopsy specimens from patients with ac-
quired AVS (13). C. pneumoniae has also been suspected of
being the etiologic agent in cases of bacterial culture-negative
endocarditis, and an association with myocarditis has been
documented (14–16).
We studied the presence of C. pneumoniae both in aortic
valves with varying degrees of macroscopic disease and in
grossly normal control valves by immunohistochemistry (IHC),
electron microscopy (EM) and polymerase chain reaction
(PCR).
Methods
Patients. The present series consists of aortic valve speci-
mens with varying degrees of macroscopic disease obtained
from a total of 35 subjects. Seventeen of these were consecu-
tive patients undergoing aortic valve replacement for the
treatment of nonrheumatic AVS in the Department of Sur-
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gery, Oulu University Hospital. In addition, aortic valve tissue
was obtained from 18 age-matched cadavers at autopsy in the
Department of Forensic Medicine or Department of Pathology
at Oulu University and Oulu University Hospital. In accor-
dance with the studies of Otto et al. (1), macroscopic disease
severity was classified as 1) absent (translucent, flexible leaflets
with no opaque areas); 2) mild to moderate (opaque leaflets
with focal areas of thickening and increased stiffness but no
significant obstructions); and 3) severe (definite areas of
calcification and thickening with clinical evidence of obstruc-
tion. Macroscopic analysis was performed in blinded manner
with regard to further analyses of the specimens. All surgical
specimens had severe lesions (group A). Ten of the 18 cadaver
aortic valves proved to be of mild to moderate degree macro-
scopically (group B). In 2 of these 10 cases significant calcifi-
cation was also seen, but none of cases had gross evidence of
significant obstruction. In 8 of 18 valves, no macroscopic
disease could be detected, and this group was selected as the
control group (group C).
Management of the valve leaflets was as follows: one leaflet
was designated for histologic studies (formalin-fixed, paraffin-
embedded). A second leaflet was immersed in 10% buffered
formalin for IHC. In addition, a portion of the leaflets ob-
tained from the surgical group was immersed in liquid nitrogen
to determine PCR. In three additional specimens of this group,
segments were fixed in a glutaraldehyde-formaldehyde mixture
for EM study. Finally, a piece of the valve tissue was used for
microbiologic analysis by conventional aerobic and anaerobic
bacterial culture. In all patients undergoing the operation,
blood specimens were obtained before the procedure for
antibody measurements. In the cadaver groups, only histology
and IHC could be performed. The protocol was approved by
the Ethical Committee of the Faculty of Medicine at the
University of Oulu.
Immunohistochemical analysis. The IHC of the formalin-
fixed, paraffin-embedded tissues was studied by the
strepavidin-biotin-peroxidase method of Hsu et al. (17) using a
Vectastain ABC kit (Vector laboratories). Chlamydia genus–
specific mouse monoclonal antibody against chlamydial lipo-
polysaccharide (LPS) antigen and C. pneumoniae–specific
monoclonal antibody RR-402 (Washington Research Founda-
tion) were used in the immunostaining process. Chlamydia
pneumoniae–infected HL cells served as positive controls and
normal skin and myometrium as negative controls. Hematox-
ylin was used as a counterstain.
Polymerase chain reaction. The tissue samples were
treated with proteinase K (Sigma) and Nonidet P-40/Tween-20
(Sigma) at final concentrations of 100 mg/ml and 0.5%,
respectively. After overnight incubation at 55°C, deoxyribonu-
cleic acid (DNA) was purified using a QIAamp tissue kit
(QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions. The oligonucleotide primers used—SC5 (59TGC-
CTGT[AG]GGGAA[TC]CC[AT][GT]CTGA[AT]CCA39)
and SCH4 (59GTCGAAAAGA[AT]AGTC[TA]CC[GA]T-
AGTA39)—modified from previously published primer se-
quences (18,19) by Dr. S. Rasmussen (University of California
at San Francisco) to be specific for C. pneumoniae and known
to amplify a 145–base pair sequence at the 59 end of the C.
pneumoniae omp1 gene, were purchased from the Institute of
Biotechnology, Helsinki, Finland. The PCR amplification mix-
ture contained 1 mmol/liter of deoxynucleoside triphosphate, 2
mmol/liter of MgCl2, 50 mmol/liter of KCl, 10 mmol/liter of
Tris-HCl (pH 8.3), 1.0 U of Taq polymerase (Hytest, Turku,
Finland), 50 pmol of each primer and 14 ml of processed and
diluted sample, with a total reaction volume of 25 ml. Ampli-
Wax beads (Perkin-Elmer Cetus) were used to facilitate the
“hot start” PCR (20). After 5 min of denaturation at 94°C, the
samples were subjected to 40 consecutive cycles of denatur-
ation (94°C for 30 s), annealing and extension (60°C for 45 s)
using a Perkin-Elmer Cetus GeneAmp 9600 thermocycler. The
final extension time after cycling had been completed was
6 min at 72°C. The PCR products were separated by electro-
phoresis on 3% agarose gels containing ethidium bromide
(0.2 mg/ml). The DNA was transferred onto a nylon mem-
brane (Immobilon N, Millipore), and the blot was hybridized
with a C. pneumoniae–specific digoxigenin-labeled probe
(59CCATAT[TA]CT[GA]CCATCAATTAA39) in 53 stan-
dard saline citrate, 1.0% (wt/vol) blocking reagent for nucleic
acid hybridization (Boehringer-Mannheim, Mannheim, Ger-
many), 0.1% N-layroylsarcosine and 0.02% sodium dodecyl
sulphate at 43°C. The hybridized probe was detected by
alkaline phosphatase–labeled antidigoxigenin Fab fragments
using 5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazo-
lium (Bio-Rad) as the substrate.
Transmission electron microscopy. The specimens for EM
were fixed in a glutaraldehyde-formaldehyde mixture (1%
glutaraldehyde and 4% formaldehyde in 0.1 mol/liter phos-
phate buffer, pH 7.4), postfixed with buffered 1% osmium
tetroxide and embedded LX 112 (Ladd). Thin sections were
cut using an Ultracut E microtome (Reichert-Jung) and post-
stained with uranyl acetate and lead citrate (Carlsberg system,
LKB, Sweden). The electron micrographs were taken with a
JEOL 1200EX transmission electron microscope operating at
60 kV.
Measurement of C. pneumoniae antibodies. Immunoglob-
ulin class–specific antibodies were measured by the microim-
munofluorescence method (21), using elementary bodies of C.
pneumoniae strain Kajaani 6 and Chlamydia trachomatis L2 as
the control antigen and fluorescein-conjugated antihuman
Abbreviations and Acronyms
AVS 5 aortic valve stenosis
CAD 5 coronary artery disease
DNA 5 deoxyribonucleic acid
EM 5 electron microscopy
Ig 5 immunoglobulin
IHC 5 immunohistochemistry
LPS 5 lipopolysaccharide
PCR 5 polymerase chain reaction
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immunoglobulin G (IgG) (Kallestad), IgA (Sigma) and IgM
(Dako A/S, Glostrup, Denmark) as conjugates.
Statistical methods. The Fisher exact (two-tailed) test was
used to compare distributions (in positive C. pneumoniae
immunostainings) between the groups. A p value , 0.05 was
considered significant.
Results
Surgical patients. Demographic data on the surgical pa-
tients (group A: 8 men and 9 women whose median age was 64
years [range 45 to 80] are provided in Table 1. Five of them
(three men and two women) had significant angiographic
evidence of CAD (.50% stenosis in at least one coronary
artery) or a distinct atherosclerotic lesion on coronary angiog-
raphy. Ten patients had tricuspid aortic valves and seven valves
were bicuspid. None of the patients had a history of rheumatic
fever, and none had any systemic illness or infection at the time
of the operation.
The histologic study of the 17 aortic valves in group A
patients showed degeneration, calcification and variable in-
flammatory cell infiltrate. Immunohistochemical staining
showed the presence of chlamydial genus–specific antigen in 15
of the 17 specimens studied, and 9 of the 17 specimens studied
were positive with C. pneumoniae species–specific monoclonal
antibody (Table 1, Fig. 1). Chlamydia pneumoniae–specific
DNA was detected by PCR in two immunohistochemically
positive specimens and in one case only was PCR positive
(Table 1). In EM studies, structures similar in morphology and
size (diameter 150 to 200 nm) to C. pneumoniae elementary
bodies were found in two of the three specimens examined,
both being positive on IHC (Fig. 2). Among the 11 patients
showing positivity with the protein antibody or by PCR or EM,
four had angiographically demonstrated CAD.
Chlamydia pneumoniae IgG antibodies in titers 8 to 512
were present in 16 serum samples, and IgA antibodies in titers
10 to 160 were present in 7 serum samples (Table 1). None of
the patients had C. trachomatis antibodies in their sera.
Aerobic and anaerobic bacterial cultures were negative in
every case.
Cadavers. Table 2 depicts pertinent demographic data,
causes of death and IHC findings of 18 cadavers. All aortic
valves obtained at autopsy proved to be tricuspid. The histo-
logic study of group B cadaver valves demonstrated degener-
ation, calcification and variable inflammatory cell infiltrates. In
6 of 10 cases these findings were very evident, and all of these
valves were positive on IHC staining with C. pneumoniae
species–specific monoclonal antibody. In each of the remaining
four cases, moderate calcification and mild inflammatory cell
infiltrates were found. Two of these four specimens were
positive on IHC (cadaver nos. 5 and 9). In two of eight of the
control valves (group C), although macroscopically normal,
light calcification was found on histologic examination. Immu-
nohistochemically, only one valve in this group was positive for
C. pneumoniae antibody. In the negative control tissues, no
positive staining was detected.
Immunostainings among the groups. Positive protein im-
munostaining was found in 9 of 17 patients (53%) with
advanced aortic valve disease requiring surgical treatment
(group A), 8 of 10 (80%) cadavers with clearly macroscopic
Table 1. Summary of Demographic Data, Presence of Tricuspid or Bicuspid Valve,
Immunohistochemical Staining, Polymerase Chain Reaction, Electron Microscopy and IgG and IgA
Antibody Titers in the Serum of 17 Consecutive Patients Undergoing Surgical Treatment for Aortic
Valve Stenosis
Pt
No. Gender
Age
(yr) CAD Valve
Immunostaining
PCR EM
Antibodies
LPS Protein IgG IgA
1 F 74 2 Bi 1 2 1 NT 23 40
2 M 70 1 Bi 1 1 2 NT 8 ,10
3 F 60 2 Tri 1 1 2 NT 128 10
4 M 63 1 Tri 1 2 1 NT 128 160
5 F 77 2 Tri 1 2 2 NT 32 ,10
6 F 69 2 Bi 1 1 1 NT 8 ,10
7 F 80 2 Tri 2 2 2 NT 128 ,10
8 M 55 1 Bi 1 2 2 NT 32 10
9 M 48 2 Bi 1 1 2 NT 32 ,10
10 F 68 2 Tri 1 2 2 NT 8 ,10
11 M 57 2 Bi 1 2 2 NT 128 160
12 M 56 2 Tri 2 2 2 NT 8 ,10
13 F 66 1 Tri 1 1 2 NT ,8 ,10
14 M 66 2 Tri 1 1 2 1 512 40
15 F 65 2 Tri 1 1 2 NT 128 10
16 M 45 2 Bi 1 1 2 2 32 ,10
17 F 72 1 Tri 1 1 2 1 8 ,10
Bi 5 bicuspid valve; CAD 5 coronary artery disease; F 5 female; IgA and IgG 5 immunoglobulin A and G,
respectively; M 5 male; NT 5 not tested; Tri 5 tricuspid valve.
1056 JUVONEN ET AL. JACC Vol. 29, No. 5
C. PNEUMONIAE IN AORTIC VALVE STENOSIS April 1997:1054–9
aortic valve pathology (group B) and 1 of 8 (12%) grossly
normal cadaver controls (group C). A clear statistical signifi-
cance regarding the presence of C. pneumoniae was found
when combined diseased subjects (groups A and B: total 17 of
27 [63%]) were compared with group C (p 5 0.018). However,
when comparing group A with group C, there was only
marginal statistical significance (p 5 0.088). Finally, there was
a strong statistical significance (p 5 0.015) when groups B and
C were compared.
Discussion
Chlamydial antigen has been previously shown to be
present in acquired valvular disease (13). The diagnosis in
those cases was based on an indirect immunofluorecence test
using polyclonal anti–Chlamydia psittaci antibodies, which very
probably contain genus-specific antibodies reacting not only
with C. psittaci but also with C. pneumoniae and C. trachomatis
(12). We demonstrated the presence of C. pneumoniae–specific
antigen or DNA in 11 (65%) of 17 stenotic aortic valves.
Furthermore, we found C. pneumoniae–specific antigen in 8
(80%) of 10 cases with clearly macroscopic aortic valve pathol-
ogy without signs of stenosis. These lesions were both macro-
scopically and histologically similar when compared with those
reported by Otto et al. (1) and were proposed to represent
“early lesions” of degenerative AVS. C. pneumoniae has been
found previously in atherosclerotic lesions of various kinds
(5,9–11), but not in CAD from chronic transplant rejection
(11). Our results show for the first time the presence of C.
pneumoniae in chronic vascular disease that is not assigned to
the atherosclerotic category. Interestingly, in the present series
the most distinct relation was found between C. pneumoniae
immunopositivity and aortic valve pathology, all cadaver con-
trol tissue with myocardial infarction as the cause of death
being C. pneumoniae negative. In the surgical series the
majority of patients did not even have clinically demonstrable
CAD.
As in investigations into the presence of C. pneumoniae in
atherosclerotic lesions, IHC was more sensitive than PCR,
which may be due to the presence of substances that inhibit
PCR in human specimens (9,10). Most of the samples gave a
positive result to the genus-specific antibody, probably recog-
nizing the chlamydial LPS. It must be emphasized that the
presence of LPS in the specimens does not necessarily indicate
C. pneumoniae, however, because LPS can incorporate into
cell membranes and be present in the circulation as a conse-
quence of an infection elsewhere (8,22,23). Moreover, sero-
logic cross-reactivity has been documented between the LPS of
Chlamydia and Bartonella species, and it is not inconceivable
that some of our patients who tested positive for LPS antibody
but negative for other C. pneumoniae indicators could have
had Bartonella or C. psittaci LPS material in their aortic valves
(24,25).
Possible relevance of C. pneumoniae in aortic valve lesions.
In their examination of “early lesions” of valvular aortic
stenosis, Otto et al. (1) demonstrated an active inflammatory
process with some similarities and dissimilarities to atheroscle-
Figure 2. Electron micrograph of stenotic aortic valve showing
Chlamydia-like particles. CM 5 cytoplasmic membrane; OM 5 outer
membrane; PS 5 periplasmic space. Bar 5 0.2 mm (35% reduction).
Figure 1. Immunostaining of a stenotic aortic valve with Chlamydia
species–specific monoclonal antibody, showing a positive reaction (A).
There is no staining in normal aorta (B).
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rosis in the valves (26). They suggested that AVS may be at
least partly initiated by mechanical injury, mediated by lipid
infiltration and chronic inflammation and further character-
ized by an accumulation of extracellular matrix secreted by
resident fibroblasts in response to inflammatory injury. Olsson
et al. (2) demonstrated the presence of activated T lympho-
cytes in tricuspid stenotic aortic valves, a finding suggesting
that immunologic mechanisms may be involved in the etiology
of nonrheumatic AVS.
It must be admitted that the present results, although
suggesting the presence of C. pneumoniae in diseased aortic
valves, do not establish the etiologic relation between the two.
It is possible, of course, that C. pneumoniae infections may only
be passengers that lodge in diseased tissue, but previous
findings demonstrating the inflammatory nature of AVR,
considered together with the present findings, support the old
hypothesis that infection may be a contributory factor, at least
in some cases of chronic valvular heart disease (13). C.
pneumoniae is a good candidate for a co-offender. Chlamydias
can damage heart tissue, causing acute and subacute valvular
and other heart infections (12), and persistence is a well-known
feature of chlamydial infections (23,27). The pathogenesis of
persistent C. pneumoniae infection may bear some similarities
to that of trachoma. Up to 90% of the population of some
developing countries are infected with C. trachomatis, but its
manifestation depends on the patients’ immunologic re-
sponses, so that only a small proportion develop trachoma, the
majority being symptomless or having a mild, acute eye
infection (28). It is possible that valvular inflammations asso-
ciated with C. pneumoniae may vary from rare acute and
subacute endocarditis to chronic valvular inflammation in
immunologically suspectible persons. Lipopolysaccharides of
C. pneumoniae can provoke and/or contribute to the endothe-
lial injury, feed the inflammation and stimulate the production
of inflammatory cytokines (23).
We conclude that C. pneumoniae is frequently present in
nonrheumatic AVS. Similarly, the high number of C. pneu-
moniae infections detected in the early lesions of “degenera-
tive” AVS suggests that tis gram-negative pathogen may play
an etiologic role in the development of this disease. The
validity of this relation requires further study.
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